A Multicenter, Double-blind, Randomized, Active-controlled, Parallel-group Comparison Clinical Pharmacology Trial to Investigate the Dose of OPC-61815 Injection Equivalent to Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2018
Price : $35 *
At a glance
- Drugs Tolvaptan (Primary) ; Tolvaptan
- Indications Heart failure
- Focus Pharmacokinetics
- Sponsors Otsuka Pharmaceutical
- 29 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 28 Oct 2018 Planned End Date changed from 31 May 2018 to 1 Feb 2019.
- 28 Oct 2018 Planned primary completion date changed from 1 May 2018 to 1 Feb 2019.